After a good year, it is tough time once again for the government-owned polio vaccine maker. Revenues at Bharat Immunologicals & Biologicals Corporation Ltd (BIBCOL) have nosedived this year due to the low oral polio vaccine (OPV) order placed on it, which is the company's sole product. This has happened mainly due to two factors-one is the re-entry of a preexisting player in the Indian Oral Polio Vaccine (OPV) segment and another is the gradual incidence of polio decline in the country.

The revenue of BIBCOL slid by 42 percent from Rs 53.25 crore in 2004-05 to Rs 30.53 crore in 2005-06, but despite this the company has made a modest profit. As compared to the 144 million doses of OPV in 2004-05, the public sector undertaking supplied about 70 million doses of OPV to the National Immunization Program (NIP), run by the Department of Health, Government of India in 2005-06. BIBCOL received the order from the Department of Family Welfare, which it completed within the stipulated period.